Becton, Dickinson and Company (NYSE:BDX) Stock Rated Outperform in New Coverage at Wolfe Research

Equities researchers at Wolfe Research initiated coverage on shares of Becton, Dickinson and Company (NYSE:BDX) in a research report issued on Tuesday, Marketbeat Ratings reports. The firm set an “outperform” rating on the medical instruments supplier’s stock.

Other equities research analysts have also recently issued research reports about the company. Jefferies Financial Group reiterated a “buy” rating and issued a $210.00 price objective on shares of Becton, Dickinson and Company in a research note on Thursday, August 6th. Evercore set a $180.00 price objective on Becton, Dickinson and Company in a report on Monday, July 6th. UBS Group assumed coverage on shares of Becton, Dickinson and Company in a research report on Tuesday, July 28th. They set a “buy” rating and a $190.00 target price on the stock. Royal Bank Of Canada lifted their target price on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a “sector perform” rating in a report on Thursday, August 13th. Finally, Weiss Ratings upgraded shares of Becton, Dickinson and Company from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, September 28th. Eight research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $185.07.

Becton, Dickinson and Company Stock Performance

Shares of BDX stock traded up $1.29 during mid-day trading on Tuesday, hitting $192.03. 43,036 shares of the stock were exchanged, compared to its average volume of 2,452,186. The stock’s fifty day simple moving average is $184.26 and its two-hundred day simple moving average is $164.00. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $195.99. The stock has a market capitalization of $52.91 billion, a price-to-earnings ratio of 57.92, a P/E/G ratio of 12.93 and a beta of 0.21.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, beating the consensus estimate of $3.14 by $0.09. The business had revenue of $4.98 billion during the quarter, compared to the consensus estimate of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%. The business’s quarterly revenue was up 5.4% on a year-over-year basis. During the same period in the previous year, the business earned $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, analysts forecast that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Insider Transactions at Becton, Dickinson and Company

In other news, EVP Michael Feld sold 165 shares of the firm’s stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total value of $31,100.85. Following the completion of the sale, the executive vice president directly owned 19,720 shares of the company’s stock, valued at $3,717,022.80. This trade represents a 0.83% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas Polen, Jr. sold 4,152 shares of the firm’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the completion of the sale, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at approximately $20,380,155. This trade represents a 3.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 6,906 shares of company stock valued at $1,265,855. Corporate insiders own 0.40% of the company’s stock.

Institutional Trading of Becton, Dickinson and Company

Several large investors have recently bought and sold shares of BDX. Brown Lisle Cummings Inc. raised its position in Becton, Dickinson and Company by 9.2% during the second quarter. Brown Lisle Cummings Inc. now owns 644 shares of the medical instruments supplier’s stock worth $97,000 after acquiring an additional 54 shares during the period. Pension & Wealth Management Advisors Inc. grew its position in shares of Becton, Dickinson and Company by 12.3% in the third quarter. Pension & Wealth Management Advisors Inc. now owns 510 shares of the medical instruments supplier’s stock valued at $94,000 after purchasing an additional 56 shares during the period. Elevation Point Wealth Partners LLC grew its position in shares of Becton, Dickinson and Company by 3.7% in the second quarter. Elevation Point Wealth Partners LLC now owns 1,692 shares of the medical instruments supplier’s stock valued at $256,000 after purchasing an additional 60 shares during the period. Private Harbour Investment Management & Counsel LLC grew its position in shares of Becton, Dickinson and Company by 1.1% in the second quarter. Private Harbour Investment Management & Counsel LLC now owns 5,511 shares of the medical instruments supplier’s stock valued at $834,000 after purchasing an additional 62 shares during the period. Finally, NorthRock Partners LLC increased its stake in shares of Becton, Dickinson and Company by 2.0% during the second quarter. NorthRock Partners LLC now owns 3,295 shares of the medical instruments supplier’s stock worth $499,000 after purchasing an additional 65 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.